Skip to content

Study · Randomized controlled trial · n = 180 · 2009

2 results

Beneficial effect of luteal-phase gonadotropin-releasing hormone agonist administration on implantation rate after intracytoplasmic sperm injection.

Razieh DF, Maryam AR, Nasim T

Taiwanese journal of obstetrics & gynecology1 Sept 2009Cited by 27 (Europe PMC)

PMID19797013 (opens in a new tab)DOI10.1016/s1028-4559(09)60297-7 (opens in a new tab)PepBankPUB-19797013
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women undergoing ICSI, luteal triptorelin increased implantation rate to 12.3%, versus 7.3% with placebo.

    In plain wordsIn women undergoing ICSI, luteal triptorelin increased implantation rate to 12.3%, versus 7.3% with placebo.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseImplantation rate
    Study

    n = 180

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.1 mg once on day 3 after embryo transferAs given in this study (human).

    Measurements

    Implantation rate
    12.3%
    triptorelin
    Implantation rate
    7.3%
    placebo

    Source sentences

    Summary
    Administration of 0.1 mg of the GnRH agonist triptorelin on day 3 after embryo transfer led to a significant improvement in implantation rate (12.3% vs. 7.3%) and clinical pregnancy rate (25.5% vs. 10.0%) as compared with placebo.
    3 context sentences
    Summary · context
    One hundred and eighty women undergoing ovarian stimulation for ICSI were enrolled in this study.
    Summary · context
    Patients were randomly assigned to receive a single dose of GnRH agonist or placebo.
    Summary · context
    Implantation rate and clinical pregnancy rate were the main outcomes.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women undergoing ICSI, luteal triptorelin increased clinical pregnancy rate to 25.5%, versus 10.0% with placebo.

    In plain wordsIn women undergoing ICSI, luteal triptorelin increased clinical pregnancy rate to 25.5%, versus 10.0% with placebo.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseClinical pregnancy rate
    Study

    n = 180

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.1 mg once on day 3 after embryo transferAs given in this study (human).

    Measurements

    Clinical pregnancy rate
    25.5%
    triptorelin
    Clinical pregnancy rate
    10%
    placebo

    Source sentences

    Summary
    Administration of 0.1 mg of the GnRH agonist triptorelin on day 3 after embryo transfer led to a significant improvement in implantation rate (12.3% vs. 7.3%) and clinical pregnancy rate (25.5% vs. 10.0%) as compared with placebo.
    3 context sentences
    Summary · context
    One hundred and eighty women undergoing ovarian stimulation for ICSI were enrolled in this study.
    Summary · context
    Patients were randomly assigned to receive a single dose of GnRH agonist or placebo.
    Summary · context
    Implantation rate and clinical pregnancy rate were the main outcomes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT04174378

Luteal Phase Support In IVF Women Using GnRH Agonist

National University of Malaysian = 22229 Nov 2018 to 18 Nov 2019

IVF · Luteal Phase Defect

Trial pageClinicalTrials.govUpdated 25 Nov 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.